Long-term outcome of percutaneous transluminal renal angioplasty in transplant renal artery stenosis

Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year cli...

Full description

Saved in:
Bibliographic Details
Published inBMC cardiovascular disorders Vol. 21; no. 1
Main Authors Wongpraparut, Nattawut, Chaipruckmalakarn, Thunyarat, Tongdee, Thongtum, Jaspttananon, Archan, Vongwiwatana, Attapong, Premasathian, Nalinee, Anusonadisai, Kawin, Pongakasira, Rungtiwa
Format Journal Article
LanguageEnglish
Published BioMed Central Ltd 26.04.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. Methods This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Results Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). Conclusions We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years. Trial registration Thai Clinical Trials Registry, TCTR20200626002. Registered 26 June 2020--Retrospectively registered, Keywords: Percutaneous transluminal renal angioplasty (PTRA), Percutaneous transluminal renal angioplasty with stenting (PTRAS), Transplant renal artery stenosis (TRAS), Long-term outcome
AbstractList Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years.
Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous transluminal renal angioplasty (PTRA) and PTRA with stenting (PTRAS). Accordingly, this study aimed to investigate the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in patients diagnosed with TRAS at Thailand's largest national tertiary referral center. Methods This single-center retrospective study included kidney transplant patients treated for TRAS during January 2001 to June 2019. Clinical success was defined as (1) increase in estimated glomerular filtration rate (eGFR) > 15%, or (2) reduction in mean arterial pressure (MAP) > 15% with no decrease in antihypertensive medication, or no reduction in MAP or reduction in MAP < 15% with decrease in antihypertensive medication. Incidence of kidney transplant graft failure and transplant renal artery stenosis were also collected. Results Sixty-five cases of TRAS were identified from 1072 patients who underwent kidney transplantation. The majority (98.5%) had end-to-side anastomosis technique. Thirty-four patients had PTRA, while 31 patients had PTRAS. One-year clinical success according to renal outcome and BP reduction was 78.5% and 49.2%, respectively. Both renal outcome (79.4% vs. 77.4%, p = 0.845) and BP reduction (40.6% vs. 58.1%, p = 0.166) at 1 year were similar between the PTRA and PTRAS groups. Compared between PTRA and PTRAS, event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher for PTRAS at 1 year (82.4% vs. 100%, p = 0.025), but not significantly different at 10 years (73.5% vs. 71%, p = 0.818). Conclusions We demonstrated the 1-year clinical success, and short- and long-term event-free survival between PTRA and PTRAS in TRAS patients. One-year clinical success was found to be similar between groups. Event-free survival for composite of kidney transplant graft failure or transplant renal artery restenosis was significantly higher in PTRAS at 1 year, but similar between groups at 10 years. Trial registration Thai Clinical Trials Registry, TCTR20200626002. Registered 26 June 2020--Retrospectively registered, Keywords: Percutaneous transluminal renal angioplasty (PTRA), Percutaneous transluminal renal angioplasty with stenting (PTRAS), Transplant renal artery stenosis (TRAS), Long-term outcome
Audience Academic
Author Tongdee, Thongtum
Vongwiwatana, Attapong
Anusonadisai, Kawin
Pongakasira, Rungtiwa
Chaipruckmalakarn, Thunyarat
Wongpraparut, Nattawut
Premasathian, Nalinee
Jaspttananon, Archan
Author_xml – sequence: 1
  fullname: Wongpraparut, Nattawut
– sequence: 2
  fullname: Chaipruckmalakarn, Thunyarat
– sequence: 3
  fullname: Tongdee, Thongtum
– sequence: 4
  fullname: Jaspttananon, Archan
– sequence: 5
  fullname: Vongwiwatana, Attapong
– sequence: 6
  fullname: Premasathian, Nalinee
– sequence: 7
  fullname: Anusonadisai, Kawin
– sequence: 8
  fullname: Pongakasira, Rungtiwa
BookMark eNptUMlqwzAQFSWFJml_oCdBz2o1ki3ZxxC6QaCX3IOsxajYUrDkQ_6-CmkhhzLMm-3NY5gVWoQYLEKPQJ8BGvGSgDWSEcqgOIWaVDdoCZUEwpiAxVV-h1YpfVMKsqHtEpldDD3JdhpxnLOOo8XR4aOd9JxVsHFOOE8qpGEefVADnuwZVeh9PA4q5RP24cIoZch_86konnDKNsTk0z26dWpI9uE3rtH-7XW__SC7r_fP7WZHeiEb4sBQWbW16hwwraw0tqWGO2GkOYOuapCKc2i5dtx1TVdzC1KCYKA7qPkaPV1kezXYgw8ulsP06JM-bISACpqaNYX1_A-rmLGj1-Wtzpf-1cIP-nNruw
ContentType Journal Article
Copyright COPYRIGHT 2021 BioMed Central Ltd.
Copyright_xml – notice: COPYRIGHT 2021 BioMed Central Ltd.
DOI 10.1186/s12872-021-02015-4
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2261
ExternalDocumentID A661418528
GeographicLocations Thailand
GeographicLocations_xml – name: Thailand
GroupedDBID ---
-A0
23N
2WC
3V.
53G
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
ABUWG
ABVAZ
ACGFO
ACGFS
ACIHN
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
AEAQA
AENEX
AFGXO
AFKRA
AFNRJ
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CS3
DIK
DU5
E3Z
EBD
EBS
ECGQY
EMB
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
UKHRP
W2D
WOQ
WOW
XSB
ID FETCH-LOGICAL-g678-f1d07495abf12cae7de90d3f6d7df6d7c4517a33193cf3fb8b53e1771621cb153
IEDL.DBID M48
ISSN 1471-2261
IngestDate Thu Feb 22 23:27:33 EST 2024
Wed Jan 10 04:26:02 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-g678-f1d07495abf12cae7de90d3f6d7df6d7c4517a33193cf3fb8b53e1771621cb153
ParticipantIDs gale_infotracmisc_A661418528
gale_infotracacademiconefile_A661418528
PublicationCentury 2000
PublicationDate 20210426
PublicationDateYYYYMMDD 2021-04-26
PublicationDate_xml – month: 04
  year: 2021
  text: 20210426
  day: 26
PublicationDecade 2020
PublicationTitle BMC cardiovascular disorders
PublicationYear 2021
Publisher BioMed Central Ltd
Publisher_xml – name: BioMed Central Ltd
SSID ssj0017809
Score 2.2927976
Snippet Background Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between...
Endovascular treatment is standard of care for transplant renal artery stenosis (TRAS). No study has evaluated long-term outcomes compared between percutaneous...
SourceID gale
SourceType Aggregation Database
SubjectTerms Angioplasty
Care and treatment
Comparative analysis
Diagnosis
Methods
Patient outcomes
Renal artery obstruction
Title Long-term outcome of percutaneous transluminal renal angioplasty in transplant renal artery stenosis
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwEA5zgvgi_sTpHHkQfIqaNG3SB5EpjiHOB9lg-DLSNBkDSWfbgfvvvdQOJwxfDkrSUvLl7r4jlzuELgNtjdSMExXwlICHkCQxsSEAvTZhpCNZ1ZkdvEb9EX8eh-MGWrU7qhew2Bja-X5So_zj-utzeQ8Kf1cpvIxuCrCxghGfbADkh4aEb6Ft5gtz-VQ-_nuqIGSV8kHBIBOgHXR1iWbjN2obveZtevtor6aJuPuD6wFqGHeIdgb1QfgRSl8yNyXerOJsUcKuMTizeG5yvQC2ZyCcx6X3QmB6fNsrnBsvlZvOsjnw5XKJZ-5nBjy6cjXu8zuXGIB3WTErjtGw9zR87JO6YQKZgs8hlqZACOJQJZYyrYxITXybBjZKReqF5iEVKgClA4QCm8gkDAwVvoYU1QmYvhPUdJkzpwhzy5UQljOlDA95pKyWTFnGE3B1Oopb6MovzsTjAj-rVZ3MD2_7elKTrnf7_l62bKH2n5mwe_Xa8Nn_w-dol1WYcMKiNmqW-cJcAAsok04VPXcqgEG-Pbx_AzIqsds
link.rule.ids 315,783,787,867,24332,27938,27939
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+outcome+of+percutaneous+transluminal+renal+angioplasty+in+transplant+renal+artery+stenosis&rft.jtitle=BMC+cardiovascular+disorders&rft.au=Wongpraparut%2C+Nattawut&rft.au=Chaipruckmalakarn%2C+Thunyarat&rft.au=Tongdee%2C+Thongtum&rft.au=Jaspttananon%2C+Archan&rft.date=2021-04-26&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2261&rft.eissn=1471-2261&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12872-021-02015-4&rft.externalDocID=A661418528
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2261&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2261&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2261&client=summon